Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations Routine +

Else Nutrition kicks off a Manufacturing Drive in Q2 2026

Else Nutrition Initiates Q2 Manufacturing Drive to Cure Chronic Stockouts as TSX Delisting Looms and CSE Listing Transition Begins

By The Northwire Desk — AI Analysis Jun 01, 2026 · 07:45 BABY · 0.025 ELSE NUTRITION HOLDINGS INC. J
Executive Summary
  • Else Nutrition announced the launch of a Q2 2026 manufacturing drive aimed at resolving persistent out-of-stock (OOS) issues that have constrained production and revenue.
  • The company plans to sustain the production ramp through summer 2026 and secure inventory for the remainder of the year to support the Canadian product re-launch and maintain US market momentum.
  • Management explicitly linked past cash limitations and rapid retail recovery to previous OOS events, which negatively impacted revenue and slowed growth.
  • The initiative is framed as a direct pathway to return the company to growth and achieve profitability goals, with a dual focus on sustaining US demand and re-establishing Canadian retail presence.
Material Impact
  • The June 1, 2026 announcement is a direct operational follow-up to the Q1 2026 earnings release (May 15, 2026), where management already identified OOS challenges as the primary drag on revenue ($1.5M vs $2.1M YoY).
  • While the manufacturing drive is a necessary step to address supply constraints, it is an expected execution step rather than a new catalyst. The market was already aware of the OOS headwinds and the planned production response.
  • The news does not introduce new financial guidance, breakthrough regulatory approvals, or significant capital injections. It merely confirms that the company is attempting to operationalize its previously stated turnaround plan.
  • Given the company's severely constrained liquidity ($245k cash) and negative equity, the market's reaction to routine operational updates is likely muted. The news is positive for long-term viability but does not alter the immediate risk profile.
BABY · Price
Company Overview
  • Else Nutrition Holdings Inc. develops and markets clean-label, plant-based, non-dairy, and non-soy infant and toddler nutrition products.
  • Flagship products include toddler and kids powder lines formulated with whole foods like almonds, buckwheat, and tapioca. The company has surpassed 1 million cans sold since launch.
  • The company is actively pursuing US FDA approval for its plant-based infant formula, leveraging a recent Congressional directive to streamline regulatory pathways for non-dairy, non-soy formulas.
  • Markets include the US, Canada (re-launching in 2026), and Israel (institutional hospital supply contracts).
Read the original news release →

More from ELSE NUTRITION HOLDINGS INC. J

Jun 29, 2026 · 07:30

Else Nutrition Announces CSE Conditional Approval

Financings May 15, 2026 · 13:44

Else Nutrition Margins Improve But Liquidity Crunch and TSX Delisting Signal Continued Distress

Earnings May 07, 2026 · 13:55

Distressed Exchange Transition

Regulatory Apr 15, 2026 · 07:30

Else Nutrition Regulatory Wins Fail to Halt Penny Stock Slide Amid Cash Burn Concerns

Regulatory Mar 10, 2026 · 16:36

Else looks to develop potential infant formula in U.S.

Regulatory Mar 10, 2026 · 07:00

Else Nutrition Expected to Benefit from FDA Regulatory Progress on Infant Formula Protein Standards

Regulatory